Abstract: A novel methodology is proposed for continuous monitoring of efficacy data in ongoing antidepressant clinical trials and for decision making to support progression or discontinuation of the trial or one of the treatment arms.
INTRODUCTION
Failed and negative trials are a recognized problem for the clinical development of novel antidepressant treatments. A trial is considered failed when the active treatment does not differentiate from placebo.
The reasons for the increasing number of negative or failed efficacy studies in Major Depressive Disorders (MDD) are poorly understood [1] . Contributing factors include, among other reasons, escalating placebo response rates, suboptimal dosing regimens, poor sensitivity of the clinical scores used to evaluate clinical efficacy (HAMD, MADRAS) and the inherently high statistical variance of studies, especially in the case of massive multi-centre trials [2, 3] .
Another confounding factor specific to clinical trials in MDD is the lack of accurate and specific diagnosis criteria. This lead to a wide margin of subjectivity in patient selection and to an increased heterogeneity (inter-individual variability) in the MDD patient population enrolled in the trials; all factors that increase the risk of study failure by Traditionally, the clinical trial design used to assess antidepressant efficacy is a randomized, double-blind, parallel-group, placebo-controlled study. This study design may not be the most efficient way to conduct a trial in MDD given the wide range of factors affecting the final study outcomes. For this purpose alternative strategies have been proposed based on the use of an adaptive approach [4] . Flexible or adaptive designs can offer an opportunity to the implementation for a learning/confirming paradigm [5] in the early stage of development of antidepressant drugs.
The data that accumulate during an ongoing clinical trial contain information about study outcomes already at a relatively early stage. The current approaches for data analysis rarely consider the use of this information to improve the overall efficiency of clinical trial. In contrast the Bayesian methodology could represent an ideal approach to capture early information that accrues during a trial, offering the opportunity to modify the study design, to stop or expand accrual, to unbalance randomization in favour to betterperforming therapies, to drop treatment arms, or change the trial population to focus on patient subsets that are responding better to the experimental therapies [6, 7] . The availability of reliable electronic data capture technology is making monitoring approach feasible in the conduction of current clinical trials [8] .
Interim monitoring is currently recognised as an important tool for early decision-making during the conduction of clinical trials [9, 10] . Most commonly, interim assessment is implemented using the group sequential [11] or stochastic curtailment approaches [12] [13] [14] . The Bayesian methodology has been used both in the group sequential [15] as well as stochastic curtailment frameworks [16] . Most Bayesian stochastic curtailment tests discussed in the literature are examples on mixed Bayesian-frequentist strategies known as predictive power tests. Choi [17] and Spiegelhalter [16] introduced early termination rules for binary endpoints based on a mixed Bayesian-frequentist approach. Berry [15] studied the use of futility rules in clinical trials with a binary outcome which are adjusted for important covariates. Johns [18] considered predictive power methods as well as methods relying on a comparison of sample proportions in clinical trials with binary outcomes. Under Bayesian and non-Bayesian assumption Spiegelhalter [19] proposed to use the Conditional Power to trigger decision at interim monitoring time. This approach is based on the conditional probability of rejecting the null hypothesis at the end of the trial. This probability can be computed under either the null or various alternative hypotheses. Recently, a generalisation of the predictive method [20, 21] , called the Bayesian predictive or Predictive Probability approach has been proposed [22] to evaluate the interim monitoring outcomes.
One of the main reasons for the growing interest in Bayesian methods is the increase in computing power and the development of simulation based approaches such as Markov chain Monte Carlo (MCMC) methods [23] [24] [25] [26] . Many of these models include hierarchical data structures where between-subject variation is modelled using random effects. Examples can be found in meta-analysis and generalised synthesis models [27] , cluster randomised trials [28, 29] , genetic epidemiology [30] , institutional ranking [31] and subgroup analysis [32] .
One important component of the Bayesian approach is the definition and selection of the appropriate 'prior information'. According to Spiegelhalter [33] , there are several possible sources of prior distributions, i.e. the Reference prior, the Sceptical prior and the Enthusiastic prior. The Reference prior or 'non-informative' represents minimal prior information. The Skeptical prior formalizes the belief that large treatment differences are unlikely. This can be set up, for example, as having a mean of no treatment effect, and only a small probability of the effect achieving a clinically relevant value. By contrast, the Enthusiastic prior can be specified, for example, with a mean effect equivalent to a clinically relevant effect, and only a small probability of no effect. The Reference prior, Skeptical prior, and Enthusiastic prior are essentially mathematical constructs, calibrated using an empirical approach. By contrast, a Clinical prior is intended to represent the current state of knowledge and it is generally based on good evidence, such as a meta-analysis of relevant randomised controlled trials [34] .
Recently FDA has recommended criteria for the assessment of scientifically valid prior information in the preparation of novel trials for the use of medical device. In this guidance, priors were considered acceptable only if the novel trial shares the same protocol design, endpoints, target population, recruitment centres of previous trials [6, 35] . These requirements are rarely fulfilled in clinical trials for the development of novel antidepressants, mostly related to logistic problems [36] . When the transferability of prior information from other studies is questionable, an alternative approach consists in building priors based on partial data accrual within a given trial. In this case uninformative prior can be used to start the Bayesian monitoring process of data accrual.
The objective of this paper was to implement a bootstrapbased methodology for decision-making based on continuous monitoring of data accumulated during clinical trials for novel antidepressants and to compare the performance of the proposed methodology with the outcomes of other approaches, such as the Conditional Power and the Predictive Probability.
MATERIAL AND METHODS
In a depression trial the primary clinical endpoint is usually defined by the changes on HAMD-17 score over time. The partial longitudinal set of measurements collected for each individual up to the monitoring time (t) constitutes the information available for data analysis represented as the information score (IS):
where i is the subject index and ji is the sequence of measurement time-points for subject i. For example, a subject with partial data collected at week 0, 1, 2 and 4 will provide [IS] 4 =7. Similarly, the total expected information score [IS] T can be estimated using the total number of subjects planned together with an estimate of the drop-out rate. Therefore, using the [IS] t /[IS] T ratio, the fraction of the total information available at a given monitoring time-point can be computed.
Within the Bayesian framework, the trial's result is driven by the posterior probability of a clinically relevant treatment effect given the available data. Based on monitoring assessment, the trial's outcome is expected to be positive if the Posterior Probability of Superiority (PPS) of the active drug versus placebo is greater than a pre-specified threshold. PPS is defined as the probability that the difference between active and placebo ( ) will be greater than 0 given X (n) (the samples observed at the monitoring assessment): PPS = Prob( > 0| X (n), prior on ) > (with 0 < < 1)
The PPS can be calculated at the different monitoring time-points during the study progression, providing estimates of the treatment effect (separation from placebo) at study-end. Moreover, the amount of cumulated information at the time of monitoring assessments can be used to decide trial termination for futility. According to Gould, decision to stop the trial for futility requires at least 40% of the total planned information [37] . After this time the predictive power (PPW, estimated using the method proposed by Dmitrienko [22] ), i.e., the probability of rejecting the null hypothesis of no treatment effect at completion of the trial based on available information can be effectively used to support a decision. If this probability is sufficiently low, then the trial could be terminated and resources redirected more productively, otherwise the trial can be progressed [38, 39] .
On this basis we can define the time for futility stopping criteria as the time when the 3 following conditions are simultaneously satisfied: 1) at least 40% of the planned information is accumulated; 2) PPS is lower than the agreed risk level of accepting superiority when this is not true (e.g. < 0.90) and 3) PPW is lower than the agreed risk level of rejecting a superiority when it is true (e.g. < 0.2).
Conditional Power and Predictive Probability
Conditional Power and Predictive Probability are estimated using a Bayesian framework by combining the data collected up to the monitoring time and a range of alternative prior assumptions. Table 1 shows the four alternatives normal priors used to evaluate the depression trials in the present analyses. These data were derived from the study design setting of the 810 trail (case 1). This trial was powered to demonstrate a clinically meaningful difference (3.5 points in the 17-item HAM-D) between paroxetine (two doses) and placebo. Sample size calculation was based on a standard deviation of 8 and normally distributed errors with a two-sided nominal significance level of 5% (actual significance level of 2.5%, adjusting for 2 treatment comparisons). The Reference prior assumes a uniform distribution and no difference between placebo and active treatments. The other priors assume a nominal difference of 3.5 in the HAMD-17 at week 8; while the standard deviation varies according to different level of expectation, i.e., arbitrarily, large for Skeptical prior, driven by sample size calculation for Clinical prior and arbitrarily small for Enthusiastic prior. Conditional Power and Predictive Probability priors were estimated using the SAS macros [39] . 
Bootstrap and Trial Simulation for Risk Assessment
Sometimes the decision to stop the trial for futility based on data not completely representative of the trial may lead to erroneous recommendations. This may occurs when a significant heterogeneity exists in the data remaining to be collected up to the study-end with respect to the data accumulated up to the monitoring time. For example, this may happen when the different centres have different starting time of recruitment, different recruitment rate and/or different quality of data.
To control the risk of a false negative decision to stop the trial, we propose a trial simulation method that uses the information available at various monitoring time points. This simulation estimates the expected PPS at the study-end for different typologies of subjects' response providing a framework to assess a scenario-based risk analysis.
The data remaining to be collected at the various monitoring time points were simulated using a nonparametric bootstrapping approach by resampling with replacement the original data collected up to the monitoring time [38, 40] . Two scenarios were considered: 1) the worst case scenario, where all the remaining subjects are assumed to show a placebo-like response, and 2) the best case scenario, where all the remaining subjects in the treatment arm are assumed to be antidepressant drug responders. Alternative intermediate scenario can be easily considered.
The Partial Database at Monitoring Time (PDMT) was initially split by treatment and only patients with a complete set of information (completers) were retained. Then, only patients responding to the treatment in the active treatment groups were selected (a responder is a patients with a HAMD-17 score reduction from baseline >=50%). These data constitute the Resampling Database (RD).
The number of unobserved patients in each treatment group was computed as the difference between the planned sample size and the number of patient included at the monitoring time (ex. Np for the placebo and Nt for the active treatment group). At this stage, bootstrap and trial simulation was implemented in a 4-step process:
1.
Resample Np and Nt subjects with replacement from the Resampling Database.
2.
Combine the Partial Database at Monitoring time with the simulated patients resampled in step 1 in a Working Database (WB) 3.
Estimate the Posterior Probability of Superiority analysing the data in the Working Database Repeat step 1 to 3 a number of time (100 for the present analysis)
4.
Compute the proportion of positive trials (the trials for which the PPS value is > 0.90). A schematic of the bootstrap process is shown in Fig. (1) .
Once the futility stopping criteria has been satisfied (at least 40% of the total information, PPS < 0.90 and PPW < 0.20), a typical decision making based on the bootstrap could be:
1.
Stop the study (or terminate one arm) if the proportion of the expected positive trials in the best case scenario is lower than 80%. The threshold was arbitrarily set based on our experience regarding study team expectation for a clinically relevant signal.
2.
Progress the study if the proportion of the expected positive trials in the best case scenario is greater than 80%. In this case, there is a reasonable chance to reverse the findings observed at monitoring time if the data remaining to be collected are particularly good.
Bayesian Longitudinal Model
The longitudinal structural model was defined as the combination of a Weibull and linear equations [41] . This model was used to fit the population HAMD-17 time-course using a Markov Chain Monte Carlo (MCMC) technique as implemented in the WinBUGS software package [25, 42] . The individual model parameters vector i was assumed to follow a normal distributions with population parameters . Specifically, was assumed diagonal and arising from Gamma distribution ( ) characterised by a relatively uninformative prior distribution (0.001, 0.001). This choice was motivated by the lack of rationale to transfer prior information from historical studies. The Bayesian analysis involved the estimation of the joint distribution of all parameters conditional on the observed data: p( , |HAMD_data). Generating random samples from the joint posterior distribution allows the marginal distribution of each parameter to be completely characterized.
Retrospective Analysis of Clinical Trial Cases
The performance of Bayesian monitoring and trial simulation was evaluated on the retrospective analysis of 3 randomized, double-blind, parallel-group, placebo controlled, multi-center clinical trials (810, GSKX, and 002) on subjects suffering from MDD, including a total of 967 subjects. The primary efficacy measure was the change from baseline to study endpoint (week 8 for study 810 and GSKX and week 6 for study 002) as measured by the HAMD-17 total score.
Case 1 (Study 810):
Efficacy and safety of paroxetine controlled release (CR) (12.5 and 25mg/day) versus placebo (N= 156, 154 and 149 respectively) were evaluated in this trial [43] . The primary efficacy analysis revealed that both the 12.5mg and the 25mg paroxetine CR treatment groups were associated with significant therapeutic effects (change in HAMD score) from baseline to study endpoint (LOCF: p = .038, 95% CI = -3.38 to -0.09 and p = .005, 95% CI = -4.06 to -0.74, respectively).
Case 2 (Study GSKX):
Efficacy and safety of fix doses of Compound X or paroxetine (20mg) to placebo (N= 125, 117 and 118 respectively) were evaluated in this trial. This study did not meet the primary objective of demonstrating statistically significant efficacy of the Compound X and paroxetine compared to placebo for the primary efficacy endpoint with an adjusted mean difference 0.25, 95% CI (-1.74, 2.23), p=0.808 for Compound X and an adjusted mean difference -0.16, 95% CI (-2.18, 1.87), p=0.879 for paroxetine. While not significant at the Week 8 observed case (OC) endpoint, numerical superiority of paroxetine over placebo was observed (adjusted mean difference -1.45, 95% CI (-3.88, 0.99), p=0.243).
Case 3 (Study 002):
Efficacy and safety of flex dose paroxetine (10-50mg/day) versus placebo (N= 138 and 135) were evaluated in this trial [44] . The primary efficacy analysis showed a significant difference between paroxetine and placebo from week 2 to week 6 on HAMD-21 change from baseline. The mean changes were -7.5, -9.4, -11.6 and Repeat 100 times the step 1, 2 and 3 Repeat 100 times the step 1, 2 and 3
Estimate the PPS on the final database -12.7 estimated on the LOCF dataset. This trial was conducted in 4 centres providing a different response. The HAMD-21 scores at week 6 failed to separate from placebo in centre 3 in contrast to what was observed in the other 3 centres. In addition a strong unbalance in subject recruitment was observed: centres 4 start the recruitment when the recruitment in the first 3 centres was almost completed (Fig.  6, right panel) .
RESULTS
The longitudinal model used for a three arms study (Placebo, Active-1 and Active-2) was:
where A is the baseline HAMD-17 score, td is the time corresponding to 63.2% of the maximal change from baseline, b is the shape or sigmoidicity factor, h rec is the recovery rate, i is the treatment arm index assuming the value of 0 (for placebo), 1 and 2 for the active arms. A total of 12 fixed-effect (μ j, j=1 to 12) parameters were estimated together with their random components j ). The treatment effect (Pred) and the treatment differences (Dpred) with their posterior distribution were then estimated using the μ j and j values:
Dpred 2 (t) = Pred 3 (t) Pred 1 (t) (6) where Dpred 1 and Dpred 2 are the predicted separation from the active arm 1 and 2 from placebo.
This model was applied to the analysis of selected clinical trials (Case 1, 2 and 3). For brevity, detailed results of individual and population longitudinal model fitting will be presented only for the Case 1 (study 810). For Case 1, 2 and 3 summary tables and graphical representation of the Bayesian monitoring and bootstrap analysis will be shown. The analysis of the Case 3 (study 002) was conducted on the HAMD-17 scores to ensure comparability of the results across the other trials presented.
Case 1 (Study 810)
The final population parameter distribution (fixed and random effect) estimated by fitting the longitudinal model to the HAMD-17 scores are shown in Table 2 .
All parameters were estimated with acceptable average precision. The treatment groups have comparable baseline values either in term of mean (fixed effect) or interindividual variability (random effect). The treatment effect was well captured by the reduction of td (the time at which a drop of 63.2% from baseline is observed) as well as by the increase in the sigmoidicity factor (b) in the paroxetine arms.
The time-course of the observed (blue) and predicted HAMD-17 scores of representative subjects are shown in Fig. (2) . Red lines indicate the median model predicted curve and the 95% credible intervals (precision of the estimate).
These results illustrate the flexibility of the longitudinal model to describe individual HAMD-17 time-course profiles showing heterogeneous patterns, such as linear increase/decrease, sigmoid decline, bell-shape time-course and exponential decrease. The results of the Bayesian monitoring (median separation from placebo in the 12.5 and 25mg paroxetine arms) conducted at different time-points with different levels of information are shown in Table 3 . The number of day from the enrolment of the first subject and the percentage of subjects remaining to be enrolled up to study termination are also shown at each monitoring time.
In this study the threshold defined by the futility stopping rule (>40% of the total information, PPS<0.90 and PPW<0.20) was never reached at any time-point. The two treatments displayed different behaviour, showing lower signal of response (separation from placebo) in the 12.5mg paroxetine arm.
In presence of a strong drug effect, as delivered by the 25mg paroxetine arm, the median separation from placebo at the study-end was already anticipated when only 18% of the total information was available. The robustness of the predicted treatment effect for each arm made at each monitoring time using the longitudinal model was illustrated by an example, i.e., the comparison of the predictions obtained with the complete and the partial dataset (18% and 100% of total information, referring to monitoring day 80 and 172, respectively) ( Table 2 ). The good agreement between the median curves estimated using the complete and partial dataset indicates the robustness of the proposed longitudinal model to describe the HAMD-17 time-course.
Bayesian inference on treatment effect at various timepoints was obtained by analysing the posterior distribution of the time-course of the difference between placebo and paroxetine in the 12.5mg and 25mg arms. As an example, the estimated time-course of these differences with the associated 95% credible intervals are shown at monitoring day 110 (51% of total information) in Fig. (3) . The good predictive performance of the model is illustrated by the location of the median response and by the size and location of the credible intervals. In fact, the median curves defined by the incomplete dataset (monitoring day 110, blue lines) consistently overlaps with the median curves estimated with the full dataset (monitoring day 172, red line) and the 95% credible intervals of the full dataset (cyan shaded area) are included in the 95% credible intervals of the incomplete dataset (grey shaded area). As expected, the size of the 95% credible interval is function of the amount of the information, showing larger spread in the estimation done at monitoring day 110. The distance of the upper bound of the 95% credible interval from the zero line is a graphical indicator of the clinical relevance of the separation from placebo. In Fig. (3) the upper bound of the 95% credible interval of the 25mg arm estimated at monitoring day 110 is just above or overlapping the zero line suggesting a strong signal of clinical efficacy at the study-end. The probability of observing HAMD-17 separation from placebo of the paroxetine treatment at study-end was estimated using the bootstrap-based trial simulation approach at each monitoring time. This probability was estimated as the percent of positive out of 100 simulated trials (probability of success). Scenario analysis was carried out assuming that the 'Worst Case' and the 'Best Case' were close to the 'Skeptical' and the 'Enthusiastic' assumptions, respectively. Fig. (4) shows the percent of positive trials by treatment for a given PPS in the best and the worst case scenario evaluated when 35% of the total information (monitoring day 96) were available. Assuming an agreed target PPS of 80% for detecting treatment superiority, the probability of success in the Worst Case scenario (left panel) was 85% for the paroxetine 25mg arm (red curve) and 42% for the paroxetine 12.5mg arm (blue curve). In the Best Case scenario (right panel) the probability of positive results was > 95% for both arms. This result indicates that even in the unlikely event that all the subjects remaining to be enrolled in the active treatment arms will respond as those receiving placebo (Worst Case scenario), there is still a high expectation of positive outcome for the 25mg paroxetine arm Placebo-4
at study-end when this assessment is performed with very limited information (<40%).
The performance of the bootstrap approach was compared with the outcomes of the Conditional Power and Predictive Probability when 35% of the total information was available ( Table 4 ). All methods provided similar estimates of the outcome for the 25mg paroxetine, a wellknown clinically effective dose [45] . Conversely, when the sub-clinical dose of 12.5 mg paroxetine was analysed, in presence of a weaker signal, only the bootstrap approach was sensitive to the different priors. Instead, Conditional Power systematically overestimated the rate of positive treatment results, while Predictive Probability systematically underestimated them. 
Placebo-25mg
As a conclusion, if the bootstrap-based monitoring approach were applied to Case 1 the recommendation at each monitoring time would have been to progress recruitment up to the planned study-end. This recommendation resulted from the combined evaluation of the PPS, the application of the futility stopping rule, and the bootstrap-based risk analysis. 
Case 2 (Study GSKX)
The results of the Bayesian monitoring (median separation from placebo in paroxetine and Compound X arms) conducted at different time-points with different levels of information are shown in Table 5 . The number of day from the enrolment of the first subject and the percentage of subjects remaining to be enrolled up to study termination are also shown at each monitoring time.
The futility criteria (>40% of the total information, PPS<0.9 and PPW<0.2) for both arms were met at monitoring day 208, when 54% of the total information was available.
Data up to day 208 were used to estimate the time-course of the median separation from placebo for the Compound X and paroxetine arms with the associated 95% credible intervals (Fig. 5) . The location of the median separation from placebo, the size of the 95% credible intervals and the distance of the upper bound of the 95% credible interval from the zero line clearly indicate that there is no reasonable expectation for a clinical effect of Compound X. Similar considerations apply to paroxetine, but to a lesser degree, since the median change showed a trend towards clinical improvement.
Subsequently, the bootstrap trial simulation was performed to assess the risk of a false negative decision. The results of this analysis indicated that the percentage of expected positive trials in the worst and best case scenario for Compound X were 0% and 16% and for paroxetine were 6% and 100%, respectively. The performance of the bootstrap approach was compared with the outcomes of the Conditional Power and Predictive Probability when 54% of the total information was available ( Table 6 ).
These data support the decision to terminate the Compound X arm (and by the consequence the entire study) considering that, even in the very optimistic event to include only responders (best case scenario), the final study outcome Fig. (5) . Posterior probability of separation from placebo for the Compound X and the Paroxetine arm with the 95% credible intervals. The solid blue and red lines represent the median separation from placebo. The grey area corresponds to the estimate done at the end of the study on all the available data while the cyan area corresponds to the analysis conducted when 54% of the total data were available. 
Case 3 (Study 002)
The results of the Bayesian monitoring (median separation of paroxetine from placebo) conducted at different time-points with different levels of information are shown in Table 7 . The number of day from the enrolment of the first subject and the percentage of subjects remaining to be enrolled up to study termination are also shown at each monitoring time.
The futility criteria (>40% of the total information, PPS<0.9 and PPW<0.2) was met at monitoring day 312, when 51% of the data were available. At this time, a consistent fraction of subjects remained to be recruited (49% in the placebo and 43% in the paroxetine arm). Therefore, it was decided to collect extra information (~10%) to increase the confidence in the decision process. At monitoring day 373, when 61% of the data was collected, the futility stopping criteria was again confirmed. At this time-point only 3 centres had been recruiting. Data up to day 373 were used to estimate the time-course of the median separation of paroxetine from placebo with the 95% credible intervals (Fig. 6, left panel) . In this figure, the location of the median separation from placebo, the size of the 95% credible intervals and the distance of the upper bound of the 95% credible interval from the zero line indicate a trend for clinical improvement, supporting the decision indicated by application of the futility rule to stop the study. The results of the bootstrap trial simulation conducted at monitoring day 373 showed that the percentage of the expected positive trials was 100% in the best case scenario (all responders) and 21% in the worst case scenario (all subjects showing a placebo-like response). The performance of the bootstrap approach was compared with the outcomes of the Conditional Power and Predictive Probability when 61% of the total information was available ( Table 8 ).
These data indicated that, by study-end, there is a reasonable chance to obtain a clinically relevant separation from placebo. In fact, recruitment in the 4 th centre started only after day 380 (Fig. 6, right panel) , significantly contributing to the final success of the study. Therefore, the results of the bootstrap trial simulation (as well as of the other methods) supporting the progression of the trial reversed the recommendation to stop the trial based on the application of the futility rule at monitoring day 373. 
DISCUSSION
A model-based approach has been proposed as a tool for decisions making on termination, progression or adaptation of clinical trials in MDD by monitoring data accrual during the conduction of a trial.
The mixed Weibull/linear equation was identified as the most accurate model to describe the HAMD-17 longitudinal scores, consistently with recent analysis of placebo response in MDD trials [41] . This model adequately described not only the average treatment response but also the individual HAMD-17 time-course as shown by the comparison of the observed and model predicted scores, the goodness of fit plots, and the accuracy of the estimated parameters. The individual model predictions provided evidence supporting the flexibility of the model for the description of heterogeneous HAMD-17 time-course patterns (trajectories), such as linear increase/decrease, bell-shape and exponential decrease observed in the different treatment arms. In addition, the analysis conducted on the truncated databases at different calendar dates before study-end (simulating the accrual process) demonstrated the good predictability properties of the model when only partial data were available.
The good predictability properties of the model were used to implement a monitoring strategy aimed to support decision making during clinical trials in MDD. Data monitoring is today an established component of good practice in clinical trials [46] [47] [48] . Many statistical approaches have been proposed to data monitoring. Frequentist methods entail calculating critical values for the interim analyses that ensure maintenance of the desired Type I error over the repeated significance tests [49] [50] [51] . In contrast to these approaches, Bayesian methods provide a framework for incorporating and updating prior beliefs about drug/placebo effects as a function of the accumulated data [52] . The most commonly used Bayesian methods are the Conditional Power [34] and the Predictive Probability [22] . The decisions driven by the Conditional Power and Predictive Probability approaches remain highly correlated with the degree of subjective judgment employed to define the prior distribution settings. In alternative to these approaches, the bootstrap-based method tries to overcome these limitations by using data-driven priors. These priors were derived from the accrued data during the progression of the trial.
The decision making process is often based on a scenario analysis. This methodology provides an assessment of the risk of study success/failure by using boundaries for possible outcomes estimated with the best and the worst expectations and beliefs. In the Bayesian framework, the best case scenario is associated with optimistic expectation (i.e., Enthusiastic) while the worst case scenario is associated with pessimistic expectation (i.e., Skeptical).
In the Bootstrap-based method, the 'Skeptical' scenario assumes that the data remaining to be collected at the various monitoring time-points show a placebo-like response while the 'Enthusiastic' scenario assumes that all the remaining subjects in the treatment arm are drug responders. The method does not require parametric assumption on the shape of the distributions. Individual data are generated using nonparametric bootstrapping approach by resampling with replacement the original data collected up to the monitoring time. In the present work we compared the performances of three methods: Conditional Power, Predictive Probability, and Bayesian bootstrap.
In case of strong clinical signal (25mg paroxetine arm in study 810), all methods provided similar estimates of the risk to continue/discontinue the trial with no differences between worst and best scenarios. In case of week clinical signal (12.5mg paroxetine arm in study 810), only the bootstrap approach was sensitive to different priors, while Conditional Power systematically overestimated the rate of positive treatment results, and Predictive Probability systematically underestimated them. The results of the analysis are consistent with results recently published, showing that predictive probability decision rules based on 'Enthusiastic' priors are more likely to trigger an early stopping in futility monitoring [22] . Thus, over-Enthusiastic prior would be required for an appropriate decision making. In contrast, the Conditional Power overestimates the rate of positive trial outcomes (including when a 'Skeptical' scenario is considered), leading to unjustified recommendations to progress trial [22] .
In the present work, the decision to discontinue a treatment arm or a trial for futility was based on the availability of about 40% of the total information and on the joint assessment of PPS and the predictive power (PPW), estimating the probability of rejecting the null hypothesis of equal treatment effects at the study-end given the interim observations and the assumptions about the prior distributions of the treatment effects.
This decision-making methodology was tested by conducting a retrospective analysis of 3 clinical trials. In the first trial (810) the conditions for discontinuing arm/trail for futility were never reached at any monitoring time-points. The strong signal of separation of the 25mg paroxetine arm from the placebo arm was estimated using bootstrap trial simulation with <35% of the total information collected in the trial. In the second trial (GSKX) a novel compound (Compound X) was tested in MDD. The criteria for discontinuing the Compound X arm was met at both 39% and 54% of total information. The bootstrap trial simulation estimated a success rate of 16% in the best case scenario, triggering the recommendation to stop the Compound X arm and, hence, to an early discontinuation of the trial. In the third trial (002) we provided an example of deviation from the exchangeability assumption due to the late inclusion of an extensively recruiting centre. The criteria for futility discontinuation were reached at both 51% and 61% of total information. However, the bootstrap trial simulation estimated a success rate of 100% and 21% in the best and the worst case scenario, respectively, recommending the continuation of the trial.
One of the critical issues in antidepressant drugs development is the complexity and relatively long duration of clinical trials (2 years on average). These factors represent serious drawback for the implementation of an effective portfolio management strategy. In early clinical development, 'Proof of concept' and signal detection trials are carried out to determine if a treatment is clinically active or inactive before commitment of investment in late phase drug development. In this framework, the possibility of an early detection of lack of efficacy can trigger the decision to terminate the trial, to discontinue the development of the drug under investigation, and, more effectively, to redirect resources more productively. If the estimated probability of success is high, the clinical development plan can be accelerated by an early initiation of confirmatory trials without affecting the course of the PoC trial in any way. On this basis, the proposed methodology can constitute a novel alternative decision-making tool to improve the overall productivity of drug development by re-directing the (sometime limited) resources in the most promising projects.
In conclusion, the comparisons of Condition Power and Predictive Probability approaches indicated that the Bayesian bootstrap method, based on data-driven assumptions for priors, provided a better control for the risk of inappropriate decisions. These results suggest that the proposed approach to monitor the accumulating information could constitute a valuable alternative to the re-engineering of the development process of novel antidepressant drugs. The WinBUGS code for longitudinal models and the code used to implement the bootstrap trial simulation can be provided upon request from the authors.
